Ah, biology and AI, the ultimate power couple. As data-loving machines, AI is transforming the drug development process, making it faster and cheaper. I mean, why wouldn’t you want to apply AI to the treasure trove of data that is the human body? It’s a match made in heaven.
Just like computers, we humans are basically walking bundles of data. Our DNA is like a sequence of As, Gs, Cs, and Ts the four base types that make up our DNA molecules. And AI, being the data-crunching machines they are, can have a profound impact on the human body.
You see, it takes about $900 million and 13.5 years to develop a new successful drug. Talk about an expensive and time-consuming process. But with AI, we can significantly reduce the time and cost of finding new drug candidates.
Take, for example, Japanese pharma giant Takeda Pharmaceutical. Earlier this year, they bought an experimental psoriasis drug for $4 billion€ a drug that was created in just six months using AI. And they’re not the only ones. Pharma giants like Bayer, Roche, Sanofi, and AstraZeneca are also using AI for drug discovery purposes.
We’re talking about investments in AI-powered drug discovery tripling over the past four years to nearly $25 billion. And Morgan Stanley predicts an additional 50 novel therapies will hit the market over the next decade, with annual sales exceeding $50 billion. The future of AI-powered drug discovery is now, folks.
So, is your portfolio ready to ride the AI biotech wave? Because this power couple is about to change the world seriously.
